| Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma |
| Ongoing | 3 | 80 | Europe | Retisert, Retisert, Retisert | National Institutes of Health, National Eye Institute | Non-infectious uveitis (inflammatory eye disease) | | | | |
2011-001078-25: Long term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation. |
|
|
| Ongoing | 3 | 31 | Europe | Retisert, C05AA10, Retisert, Retisert | National Institute of Health, National Eye Institute, National Institute of Health, National Eye Institute | Non-infectious pan, intermediate and posterior uveitis (inflammatory eye disease) | | | | |
| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap |
NCT04781335: "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation" |
|
|
| Recruiting | 4 | 50 | US | Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID) | The Eye Institute of West Florida, EyePoint Pharmaceuticals, Inc. | Cataract | 06/21 | 08/21 | | |
NCT05191706: Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract |
|
|
| Recruiting | 4 | 60 | US | Dexamethasone, Prednisolone Acetate Ophthalmic | EyePoint Pharmaceuticals, Inc. | Cataract | 01/25 | 02/25 | | |
NCT06429306: Study of Dexycu in Treating Intraocular Inflammation |
|
|
| Completed | 3 | 285 | RoW | Dexycu, Investigational product, Placebo | Ocumension Therapeutics (Shanghai) Co., Ltd | Inflammation, Cataract | 11/23 | 04/24 | | |
NCT05550363: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) |
|
|
| Withdrawn | 3 | 150 | NA | Dexycu, Placebo/Vehicle | EyePoint Pharmaceuticals, Inc. | Cataract | 09/23 | 09/23 | | |
NCT05550350: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery |
|
|
| Not yet recruiting | 3 | 150 | NA | Dexycu, Placebo/Vehicle | EyePoint Pharmaceuticals, Inc. | Cataract | 04/24 | 04/24 | | |
SELVEDge, NCT05530421: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 2 | 33 | US | Selinexor, Xpovio, Venetoclax, Venclexta, Venclyxto, Dexamethasone, Decadron, Ozurdex, Dexycu | University of Miami, Karyopharm Therapeutics Inc | Relapsed and Refractory Multiple Myeloma | 03/26 | 03/28 | | |
| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma |
2016-004488-38: Investigation of the influence of the corticosteroid agent Iluvien on inflammation and growth factors in the eye of patients suffering from diabetic-related retina damage with swelling of the centre of the retina Untersuchung des Einflusses des Kortikosteroid-Medikamentes Iluvien auf die Entzündungs- und Wachstumsfaktoren im Auge von Patienten, die untereiner Diabetes-bedingten Netzhautschädigung mit Schwellung der Netzhautmitte leiden |
|
|
| Ongoing | 4 | 12 | Europe | Intravitreal implant in applicator, ILUVIEN 190 Mikrogramm intravitreales Implantat im Applikator | J. W. Goethe University, represented by dean of the medical faculty, Alimera Sciences Ophthalmologie GmbH | Diabetic related Macula edema Diabetisches Makulaödem, Diabetic-related retina damage with swelling of retina centre Diabetes-bedingte Netzhautschädigung mit Schwellung der Netzhautmitte, Diseases [C] - Eye Diseases [C11] | | | | |
2020-005100-18: Comparaison de 2 traitements de référence sur les œdèmes maculaires diabétiques résistants, persistants malgré un traitement bien conduit depuis plus de 2 ans |
|
|
| Not yet recruiting | 4 | 106 | Europe | Intravitreal implant in applicator, Iluvien, OZURDEX | CHU Dijon Bourgogne | Œdème maculaire diabétique, Œdème maculaire diabétique, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04469595: A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) |
|
|
| Active, not recruiting | 4 | 300 | US | Iluvien 0.19 MG Drug Implant, ILUVIEN, Aflibercept, Eylea | Alimera Sciences | Diabetic Macular Edema | 12/24 | 12/24 | | |
2022-001622-29: A Multicentre Study to Evaluate the Safety and Efficacy of the Eye Implant ILUVIEN® in Children with non-infectious uveitis affecting the posterior segment of the eye Estudio multicéntrico para evaluar la seguridad y la eficacia del implante ocular ILUVIEN® en niños con uveítis no infecciosa que afecta el segmento posterior del ojo |
|
|
| Not yet recruiting | 3 | 25 | Europe | ILUVIEN 190 micrograms intravitreal implant in applicator, Intravitreal implant in applicator, ILUVIEN 190 micrograms intravitreal implant in applicator | Alimera Sciences Europe Limited, Alimera Sciences Europe Limited | Non-Infectious Uveitis affecting the posterior segment Uveítis no infecciosa que afecta el segmento posterior del ojo, Non-Infectious Uveitis affecting the posterior segment Uveítis no infecciosa que afecta el segmento posterior del ojo, Diseases [C] - Eye Diseases [C11] | | | | |
2016-002523-28: A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa. |
|
|
| Ongoing | 2 | 20 | Europe | Iluvien, n/a, Implant, Iluvien | Moorfields Eye Hospital, Alimera Sciences | Retinitis Pigmetosa., Inherited form of eye disease., Body processes [G] - Genetic Phenomena [G05] | | | | |
| vorolanib (EYP-1901) / EyePoint Pharma |
| Active, not recruiting | 2 | 160 | US | Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea | EyePoint Pharmaceuticals, Inc. | Wet Age-related Macular Degeneration | 11/23 | 04/24 | | |
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) |
|
|
| Recruiting | 2 | 105 | US | EYP-1901, Sham IVT | EyePoint Pharmaceuticals, Inc. | Nonproliferative Diabetic Retinopathy | 02/24 | 08/25 | | |
| Not yet recruiting | 2 | 25 | NA | EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph | EyePoint Pharmaceuticals, Inc. | Diabetic Macular Edema | 01/25 | 01/25 | | |
| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma |
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis |
|
|
| Recruiting | 4 | 125 | US | Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg | Alimera Sciences, CBCC Global Research | Uveitis, Posterior | 11/25 | 11/25 | | |
NCT05070728: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) |
|
|
| Terminated | 3 | 12 | US | Sham Injector, Sham Comparator, FAI Insert, Active Drug | EyePoint Pharmaceuticals, Inc. | Uveitis, Uveitis, Posterior, Uveitis, Intermediate | 10/22 | 04/23 | | |
TYNI, NCT05486468: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment |
|
|
| Recruiting | 3 | 30 | US | Yutiq 0.18 MG Drug Implant, Sham Injection | Texas Retina Associates, Eye Point Pharmaceuticals | Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate | 12/23 | 12/24 | | |
NCT04918121: A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery |
|
|
| Recruiting | 1 | 5 | US | Yutiq 0.18 MG Drug Implant | Sanjay Asrani | Glaucoma | 12/24 | 12/24 | | |
NCT05592717: A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis |
|
|
| Recruiting | N/A | 15 | RoW | Yutiq | Tianjin Medical University | Uveitis, YUTIQ | 11/25 | 11/26 | | |
